Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

4.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Lamin B1 safeguards the B cell genome and shapes lymphoma outcome.

HemaSphere·2026
Same author

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Leukemia·2026
Same author

Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148].

Neoplasia (New York, N.Y.)·2026
Same author

Intracellular Oxidant Levels Are Crucial for Cell Survival and JAK/STAT Signaling in Classical Hodgkin's Lymphoma.

Antioxidants (Basel, Switzerland)·2026
Same author

<i>Erratum</i> to: "Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance".

Haematologica·2025

Related Experiment Video

Updated: Aug 30, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.5K

Targetable alterations in primary extranodal diffuse large B-cell lymphoma.

Stephanie E Weissinger1,2, Rucha Dugge1, Miriam Disch1

  • 1Institute of Pathology University Hospital Ulm Ulm Germany.

Ejhaem
|September 2, 2022
PubMed
Summary

This study reveals that specific genetic mutations in primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) correlate with poorer survival outcomes. Understanding these biomarkers may guide targeted therapies for PE-DLBCL patients.

Keywords:
extranodal diffuse large B‐cell lymphomaimmunohistochemical analysismutational analysisprognosistargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

Related Experiment Videos

Last Updated: Aug 30, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) is a diverse group of lymphomas.
  • Investigating molecular markers is crucial for understanding PE-DLBCL heterogeneity and prognosis.

Purpose of the Study:

  • To determine the prevalence and prognostic significance of PD-L1, PD1, CD30 expression, 9p24.1 copy number, and mutations in MYD88, CD79B, CARD11, and BTK in PE-DLBCL.
  • To explore the biological distinctiveness of PE-DLBCL across various extranodal sites.

Main Methods:

  • Analysis of PD-L1, PD1, and CD30 surface expression.
  • Assessment of 9p24.1 copy number alterations.
  • Somatic mutation profiling for MYD88, CD79B, CARD11, and BTK genes.
  • Correlation of molecular markers with clinical outcomes in 116 PE-DLBCL patients.

Main Results:

  • PD-L1 expression was highest in primary mediastinal B-cell lymphoma (PMBL) (92%) and gastric lymphomas (57%).
  • High frequencies of MYD88 (46%) and CD79B (50%) mutations were observed in ear, nose, and throat (ENT) lymphomas.
  • MYD88, CD79B, and BTK mutations were associated with significantly lower overall and progression-free survival rates.

Conclusions:

  • PE-DLBCL exhibits significant biological heterogeneity.
  • Specific mutations (MYD88, CD79B, BTK) are prevalent in certain PE-DLBCL subtypes and are linked to adverse prognostic outcomes.
  • These findings support the potential for targeted therapeutic strategies in PE-DLBCL.